We have recently shown that dual inhibition of PLK1 and FGFR1 has synergistic anticancer effects in KRAS-mutant cancer cells, as FGFR1 and PLK1 cooperate control the metabolic stress associated with KRAS mutation (42). The gene discussed is FGFR1; the disease is cancer.